Patient characteristics
| Characteristic . | N = 18 . |
|---|---|
| Age, median (range), y | 64 (41-74) |
| Age category, n (%) | |
| <60 y | 7 (39) |
| ≥60 y | 11 (61) |
| Gender, n (%) | |
| Female | 8 (44) |
| Male | 10 (56) |
| Stage at diagnosis, n (%) | |
| I | 1 (6) |
| II | 4 (22) |
| III | 0 (0) |
| IV | 13 (72) |
| Baseline disease characteristics, n (%) | |
| Histology | |
| HGBCL with MYC and BCL2 and/or BCL6 rearrangement (double/triple-hit) | 6 (33) |
| DLBCL NOS | 8 (44) |
| PMBCL | 4 (22) |
| Cell of origin | |
| Germinal center B-cell–like | 13 (93) |
| Activated B-cell–like | 1 (7) |
| B symptoms | 7 (39) |
| Bulky sites (>7.5 cm) | 11 (61) |
| Extranodal disease | 14 (78) |
| Double expressor (if known) | 7 (47) |
| Elevated lactate dehydrogenase | 14 (78) |
| Eastern Cooperative Oncology Group performance status | |
| 0-1 | 18 (100) |
| 2 | 0 (0) |
| MYC rearrangement (n = 17) | 9 (53) |
| International prognostic index | |
| 0-2 | 5 (28) |
| 3-5 | 13 (72) |
| Ki-67 ≥90% (n = 15) | 5 (33) |
| Prephase prednisone use | 9 (50) |
| Diagnosis to treatment interval, median (range), d | 24 (10-37) |
| Maximum dose level achieved, n (%) | |
| 1 | 2 (11) |
| 2 | 7 (39) |
| 3 | 4 (22) |
| 4 | 3 (17) |
| 5 | 2 (11) |
| Pola dose reduction required, n (%) | 1 (6) |
| Characteristic . | N = 18 . |
|---|---|
| Age, median (range), y | 64 (41-74) |
| Age category, n (%) | |
| <60 y | 7 (39) |
| ≥60 y | 11 (61) |
| Gender, n (%) | |
| Female | 8 (44) |
| Male | 10 (56) |
| Stage at diagnosis, n (%) | |
| I | 1 (6) |
| II | 4 (22) |
| III | 0 (0) |
| IV | 13 (72) |
| Baseline disease characteristics, n (%) | |
| Histology | |
| HGBCL with MYC and BCL2 and/or BCL6 rearrangement (double/triple-hit) | 6 (33) |
| DLBCL NOS | 8 (44) |
| PMBCL | 4 (22) |
| Cell of origin | |
| Germinal center B-cell–like | 13 (93) |
| Activated B-cell–like | 1 (7) |
| B symptoms | 7 (39) |
| Bulky sites (>7.5 cm) | 11 (61) |
| Extranodal disease | 14 (78) |
| Double expressor (if known) | 7 (47) |
| Elevated lactate dehydrogenase | 14 (78) |
| Eastern Cooperative Oncology Group performance status | |
| 0-1 | 18 (100) |
| 2 | 0 (0) |
| MYC rearrangement (n = 17) | 9 (53) |
| International prognostic index | |
| 0-2 | 5 (28) |
| 3-5 | 13 (72) |
| Ki-67 ≥90% (n = 15) | 5 (33) |
| Prephase prednisone use | 9 (50) |
| Diagnosis to treatment interval, median (range), d | 24 (10-37) |
| Maximum dose level achieved, n (%) | |
| 1 | 2 (11) |
| 2 | 7 (39) |
| 3 | 4 (22) |
| 4 | 3 (17) |
| 5 | 2 (11) |
| Pola dose reduction required, n (%) | 1 (6) |